International Assets Investment Management LLC Has $747,000 Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

International Assets Investment Management LLC raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 7,880.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,666 shares of the company’s stock after acquiring an additional 5,595 shares during the quarter. International Assets Investment Management LLC’s holdings in Neurocrine Biosciences were worth $747,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in NBIX. DSM Capital Partners LLC increased its position in Neurocrine Biosciences by 15.4% during the third quarter. DSM Capital Partners LLC now owns 1,224,017 shares of the company’s stock worth $137,702,000 after buying an additional 163,747 shares during the last quarter. Braidwell LP lifted its holdings in Neurocrine Biosciences by 3.7% in the 3rd quarter. Braidwell LP now owns 968,024 shares of the company’s stock worth $108,903,000 after purchasing an additional 34,662 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its position in Neurocrine Biosciences by 59.0% during the third quarter. Jacobs Levy Equity Management Inc. now owns 692,374 shares of the company’s stock worth $77,892,000 after purchasing an additional 256,920 shares during the period. Westfield Capital Management Co. LP grew its holdings in Neurocrine Biosciences by 73.0% during the third quarter. Westfield Capital Management Co. LP now owns 649,292 shares of the company’s stock valued at $73,045,000 after purchasing an additional 273,952 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Neurocrine Biosciences by 3.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 623,267 shares of the company’s stock valued at $70,118,000 after purchasing an additional 18,334 shares during the period. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Trading Up 4.8 %

NBIX opened at $140.09 on Wednesday. Neurocrine Biosciences, Inc. has a 1-year low of $89.04 and a 1-year high of $148.37. The firm has a 50-day moving average price of $136.34 and a two-hundred day moving average price of $127.54. The stock has a market capitalization of $13.94 billion, a PE ratio of 57.89 and a beta of 0.25.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.31. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The firm had revenue of $515.20 million for the quarter, compared to analyst estimates of $518.52 million. During the same period last year, the company earned $0.88 EPS. The business’s quarterly revenue was up 25.0% compared to the same quarter last year. On average, research analysts predict that Neurocrine Biosciences, Inc. will post 4.84 EPS for the current year.

Analysts Set New Price Targets

NBIX has been the topic of a number of research analyst reports. The Goldman Sachs Group raised their target price on shares of Neurocrine Biosciences from $134.00 to $153.00 and gave the company a “buy” rating in a research note on Thursday, January 25th. Barclays raised their target price on Neurocrine Biosciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Tuesday, January 23rd. StockNews.com raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 8th. Mizuho upped their target price on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the company a “neutral” rating in a research note on Thursday, February 8th. Finally, Wedbush restated an “outperform” rating and issued a $147.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday, April 17th. Seven equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $139.67.

Insider Buying and Selling at Neurocrine Biosciences

In related news, insider Ingrid Delaet sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $145.06, for a total transaction of $725,300.00. Following the completion of the sale, the insider now directly owns 7,507 shares of the company’s stock, valued at $1,088,965.42. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Neurocrine Biosciences news, insider Ingrid Delaet sold 5,000 shares of the stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $145.06, for a total value of $725,300.00. Following the transaction, the insider now owns 7,507 shares of the company’s stock, valued at $1,088,965.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Eric Benevich sold 19,818 shares of the business’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $133.36, for a total value of $2,642,928.48. Following the transaction, the insider now owns 40,778 shares of the company’s stock, valued at $5,438,154.08. The disclosure for this sale can be found here. In the last three months, insiders have sold 186,994 shares of company stock worth $25,806,409. Company insiders own 4.40% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.